Concord Biotech Ltd.

“Concord Biotech is a best-in-class Indian specialty API manufacturer with a durable fermentation moat, debt-free balance sheet, and 25-32% ROCE sustained over multiple years — fundamentals that are genuinely rare. However, at 30x forward P/E with TTM earnings contracting -16.3% and a single-site manufacturing concentration, the current price fully reflects the quality without offering a meaningful margin of safety. The stock has corrected 47% from its 2024 peak, improving the long-term setup, but a further de-rating to 22-24x forward earnings (~INR 800-900) would represent the high-conviction entry point this business deserves. Until then, the risk/reward favors watching over buying.”